Email Updates

Search form

You are here

27 APRIL 2018 VOLUME 19 ISSUE 17

Media Coverage

  • The Committee for Medicinal Products for Human Use (CHMP) backed the treatment, Biktarvy, a once-daily tablet that combines two previously approved drugs - emtricitabine, tenofovir alafenamide and a new integrase inhibitor bictegravir.

    April 27, 2018
    Reuters
  • A team led by scientists from the University of Hong Kong has developed a new antibody drug that will not only protect people from contracting HIV but also serve as a long-acting treatment for the virus, unlike current medication that must be taken daily.

    April 26, 2018
    Antibody Related Research, PrEP, Treatment
    South China Morning Post
  • New technology involving “heat maps” that illustrate high concentrations of HIV infection are helping the Northwell Health system better target outreach in African-American communities, officials with the health network said Thursday.

    April 26, 2018
    Newsday
  • A recent report from the Centers for Disease Control and Prevention found that while 50 percent of the 1.1 million Americans ― 500,000 people ― who could benefit from PrEP were black, African-Americans accounted for only 1 percent of those filling PrEP prescriptions ― just 7,000 people.

    April 25, 2018
    Huffington Post
  • HIV-infected pregnant women had no higher risk of adverse birth outcomes when receiving tenofovir, emtricitabine, and ritonavir-boosted lopinavir (TDF-FTC-LPV/r) versus women who used other antiretroviral therapy regimens, researchers found.

    April 25, 2018
    MedPage Today
  • The HIV and AIDS epidemic could become uncontained if current funding trends continue, warned one of the founding architects of the United States President’s Emergency Plan for AIDS Relief.

    April 25, 2018
    General
    Devex
  • Since 2016, the US public health community has observed National Transgender HIV Testing Day each April 18th. In announcing its efforts in connection with the event, in an email sent out last week, the CDC shared some troubling statistics: according to the agency, 22% to 28% of transgender women are living with HIV, as are an estimated 56% of black/African-American transgender women.

    April 25, 2018
    General
    Contagion Live
  • Mosaic HIV-1 immunogens delivered via a modified vaccinia Ankara (MVA) vector elicit HIV-1-specific immune responses in healthy, uninfected volunteers, researchers report.

    April 25, 2018
    Reuters Health
  • If you want to learn about your body’s immune system, you need to look at its control center — the lymph nodes. That’s where the various cells that comprise the immune system come together and communicate to devise a plan of action to fight whatever disease might be present in the body, said UT doctoral graduate Ben Wendel.

    April 25, 2018
    Antibody Related Research, HIV Vaccine, Treatment
    Daily Texan
  • A battle is brewing in the HIV research world about the best way to prevent HIV transmission. On one side are drugs that target the tissue where exposure to the virus occurs — think a gel or douche. On the other is a whole-body approach. Think a pill or a shot.

    April 24, 2018
    PBS News Hour
  • Zimbabwean health experts and researchers are leading a regional ground breaking HIV study to determine if anti-bodies can prevent HIV infection. Laboratory tests have shown that a manufactured VRC01 antibody could prevent many different strains of HIV from infecting cells.

    April 24, 2018
    Antibody Related Research
    Chronicle
  • More specifically, the resolution urges governments and relevant private stakeholders to use appropriate legal and policy means to reduce the HIV-related social determinants. Such determinants include “poverty, stigma, discrimination, and racism; housing, food, and transportation insecurity; over-criminalization of HIV non-disclosure; and misinformation about HIV transmission risk.”

    April 24, 2018
    General
    POZ
  • A team of scientists has challenged the finding by others in the field of HIV science that a certain molecule is a biomarker of immune cells that are latently infected with the virus (meaning those cells are in a resting state and not producing new virus). On the contrary, the molecule CD32 actually indicates immune cells that are actively infected with the virus despite antiretroviral (ARV) treatment.

    April 24, 2018
    POZ
  • The "U=U" campaign states that people who have HIV cannot sexually transmit the virus if they are being treated and the virus is undetectable in their blood. Jake Maxon, who leads Hennepin County's strategy to end the HIV epidemic, says the announcement is important because it can encourage more people to get tested and stay in treatment.

    April 23, 2018
    MPR News
  • The progress made over the past 20 years to improve antiretroviral (ART) regimens making them more potent, safer and better tolerated, simpler and easier to take, and less susceptible to viral resistance has been nothing short of spectacular. While some people may think that this progress is completed and that further improvements in ART regimens are unnecessary or a waste of resources, many others, including many people living with HIV (PLWH), think otherwise.

    April 23, 2018
    BodyPro
  • Researchers at the University of Massachusetts are launching a phase 1 trial to determine the safety of a potential vaccine for HIV.

    April 23, 2018
    MD Magazine
  • The development of highly effective approaches to HIV treatment and prevention—in the form of combination antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP)—stands among the most impressive scientific achievements in human history.

    April 23, 2018
    POZ
  • The “ASEAN Cities Getting to Zero Project”, which aims at halting the spread of HIV in the region, would be extended to two new sites in Myanmar. The project is the flagship initiative of the 10-country Association of Southeast Asian Nations (ASEAN) to achieve zero new HIV infections, zero discrimination and zero AIDS-related deaths in the region.

    April 23, 2018
    General, Treatment
    Myanmar Times
  • Their biggest concern: long-standing US visa policies will prevent many of the people most affected by AIDS and HIV, including drug users and sex workers who live in other countries, from attending the conference. They also worry about new restrictions affecting travel from Muslim countries.

    April 22, 2018
    General
    NBC News
  • In the first eight months of the programme, since last July, 1295 people have been prescribed pre-exposure propylaxis (PrEP). Of these, 1254 are gay, bisexual or other men who have sex with men (MSM) and ten are women.

    April 21, 2018
    aidsmap
  • The government has revived its HIV testing guidelines of 2016 and started encouraging all family members with HIV positive patients to be screened. The use of ‘target testing’ is being promoted alongside the current UNAIDS Test and Treat strategy.

    April 20, 2018
    General
    The Observer
  • HIV prevention services such as pre-exposure prophylaxis and harm-reduction programs were offered in only about one-quarter of rural West Virginian counties, where health officials identified an increase in new infections among men who have sex with men and people who inject drugs, according to findings presented today at the CDC’s annual Epidemic Intelligence Service conference.

    April 18, 2018
    General, PrEP
    Healio
  • Researchers have discovered that HIV disables pathways between the molecules that help the body rid itself of viruses. They think that by strengthening these pathways, the body could clear itself of HIV. Present treatments can slow down or suppress HIV, but do not remove it from the body.

    April 18, 2018
    The Times
  • After years of research, professor Emmanuel Ho and his team have finished an initial phase of testing for an implant that uses the body's own immune cells to reduce the chances of infection.

    April 18, 2018
    CBC

Published Research

Announcements